Armoured CAR T-Cell Therapy Shows Promise in Resistant Lymphoma
A novel form of CAR T-cell therapy, engineered to enhance immune response, is showing encouraging results in patients with relapsed or refractory lymphoma who previously failed anti-CD19 CAR T-cell treatment.